Compare
Niagen Bioscience, Inc. vs Natural Alternatives International Inc vs Mannatech Inc vs Marimed Inc.
| Latest fiscal year | Niagen Bioscience, Inc. NAGE | Natural Alternatives International Inc NAII | Mannatech Inc MTEX | Marimed Inc. MRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $129.42M | $142.51M | $108.04M | $159.83M |
| Revenue growth (YoY) | +29.9% | +9.7% | -8.3% | +1.3% |
| Gross margin | 64.3% | 6.3% | 74.9% | 36.2% |
| Operating margin | 12.6% | -13.2% | -0.4% | -1.8% |
| Net margin | 13.4% | -14.5% | -14.1% | -9.1% |
| Net income | $17.38M | -$20.70M | -$15.21M | -$14.48M |
| EPS (Diluted) | $0.20 | -$3.43 | -$8.00 | -$0.04 |
| Operating cash flow | $13.50M | -$8.92M | -$2.96M | $7.70M |
| Free cash flow | n/a | -$12.62M | -$4.32M | $6.53M |
| Cash & equivalents | n/a | $7.39M | $6.18M | n/a |
| Total assets | $106.41M | $126.45M | $29.99M | $202.56M |
| Total liabilities | $29.87M | $76.49M | $35.22M | $137.83M |
| Shareholders' equity | $76.53M | $49.96M | -$5.22M | $50.01M |
| Return on year-end equity | 22.7% | -41.4% | n/a | -29.0% |
| Shares outstanding | 79.71M | 6.27M | 1.90M | 396.91M |
Revenue, most recent five fiscal years
| Fiscal year | Niagen Bioscience, Inc. | Natural Alternatives International Inc | Mannatech Inc | Marimed Inc. |
|---|---|---|---|---|
| Latest | $129.42M Ended 2025-12-31 | $142.51M Ended 2026-06-30 | $108.04M Ended 2025-12-31 | $159.83M Ended 2025-12-31 |
| 1 year earlier | $99.60M Ended 2024-12-31 | $129.86M Ended 2025-06-30 | $117.87M Ended 2024-12-31 | $157.71M Ended 2024-12-31 |
| 2 years earlier | $83.57M Ended 2023-12-31 | $113.80M Ended 2024-06-30 | $131.96M Ended 2023-12-31 | $148.60M Ended 2023-12-31 |
| 3 years earlier | $72.05M Ended 2022-12-31 | $154.01M Ended 2023-06-30 | $137.21M Ended 2022-12-31 | $134.01M Ended 2022-12-31 |
| 4 years earlier | $67.45M Ended 2021-12-31 | $170.97M Ended 2022-06-30 | $159.76M Ended 2021-12-31 | $121.46M Ended 2021-12-31 |